The Indian drug controller committee has given a waiver on the local clinical trials for Sofosbuvir and Ledipasvir along with Daclatasvir. Hopefully we should now have both the medicines in December 2015. These drugs are highly efficacious in the management of Hepatitis C patients with both Genotype 1 & 3.